#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4.
1-1	0-2	4.	_	_	_	_

#Text=Materials and Methods
2-1	3-12	Materials	abstract	new	_	_
2-2	13-16	and	_	_	_	_
2-3	17-24	Methods	object	new	_	_

#Text=A search was performed of regulatory and scientific literature to identify sources of clinical data to be used to compare the efficacy and safety of BRAFi/MEKi combination therapies for the treatment of BRAF -mutant metastatic melanoma .
3-1	25-26	A	event[3]	new[3]	coref	4-5[17_3]
3-2	27-33	search	event[3]	new[3]	_	_
3-3	34-37	was	_	_	_	_
3-4	38-47	performed	_	_	_	_
3-5	48-50	of	_	_	_	_
3-6	51-61	regulatory	abstract[4]	new[4]	coref	4-6[0_4]
3-7	62-65	and	abstract[4]	new[4]	_	_
3-8	66-76	scientific	abstract[4]	new[4]	_	_
3-9	77-87	literature	abstract[4]	new[4]	_	_
3-10	88-90	to	_	_	_	_
3-11	91-99	identify	_	_	_	_
3-12	100-107	sources	abstract[5]	new[5]	_	_
3-13	108-110	of	abstract[5]	new[5]	_	_
3-14	111-119	clinical	abstract[5]|abstract[6]	new[5]|new[6]	coref	6-37[0_6]
3-15	120-124	data	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-16	125-127	to	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-17	128-130	be	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-18	131-135	used	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-19	136-138	to	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-20	139-146	compare	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-21	147-150	the	abstract[5]|abstract[6]|abstract[7]	new[5]|new[6]|new[7]	coref	7-20[0_7]
3-22	151-159	efficacy	abstract[5]|abstract[6]|abstract[7]	new[5]|new[6]|new[7]	_	_
3-23	160-163	and	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-24	164-170	safety	abstract[5]|abstract[6]|abstract[8]	new[5]|new[6]|new[8]	coref	15-2[0_8]
3-25	171-173	of	abstract[5]|abstract[6]|abstract[8]	new[5]|new[6]|new[8]	_	_
3-26	174-184	BRAFi/MEKi	abstract[5]|abstract[6]|abstract[8]|abstract|abstract[11]	new[5]|new[6]|new[8]|new|new[11]	_	_
3-27	185-196	combination	abstract[5]|abstract[6]|abstract[8]|abstract|abstract[11]	new[5]|new[6]|new[8]|new|new[11]	coref	20-7[235_0]
3-28	197-206	therapies	abstract[5]|abstract[6]|abstract[8]|abstract[11]	new[5]|new[6]|new[8]|new[11]	_	_
3-29	207-210	for	_	_	_	_
3-30	211-214	the	event[12]	new[12]	_	_
3-31	215-224	treatment	event[12]	new[12]	_	_
3-32	225-227	of	event[12]	new[12]	_	_
3-33	228-232	BRAF	event[12]|abstract|abstract[14]	new[12]|new|new[14]	coref|coref	5-27|5-26[33_14]
3-34	233-240	-mutant	event[12]|abstract[14]	new[12]|new[14]	_	_
3-35	241-251	metastatic	event[12]|abstract[14]	new[12]|new[14]	_	_
3-36	252-260	melanoma	event[12]|abstract[14]	new[12]|new[14]	_	_
3-37	261-262	.	_	_	_	_

#Text=The full details of the literature search are outlined in Table S4 .
4-1	263-266	The	abstract[15]	new[15]	_	_
4-2	267-271	full	abstract[15]	new[15]	_	_
4-3	272-279	details	abstract[15]	new[15]	_	_
4-4	280-282	of	abstract[15]	new[15]	_	_
4-5	283-286	the	abstract[15]|event[17]	new[15]|giv[17]	coref	7-9[91_17]
4-6	287-297	literature	abstract[15]|abstract|event[17]	new[15]|giv|giv[17]	coref	7-11
4-7	298-304	search	abstract[15]|event[17]	new[15]|giv[17]	_	_
4-8	305-308	are	_	_	_	_
4-9	309-317	outlined	_	_	_	_
4-10	318-320	in	_	_	_	_
4-11	321-326	Table	abstract	new	coref	9-15[109_0]
4-12	327-329	S4	abstract	new	_	_
4-13	330-331	.	_	_	_	_

#Text=Four phase III studies were identified : coBRIM , a phase III trial of cobimetinib plus vemurafenib versus vemurafenib monotherapy in previously untreated patients with advanced BRAF -mutant melanoma ; COMBI-d , a phase III trial of dabrafenib and trametinib versus dabrafenib monotherapy in previously untreated patients with unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation ; COMBI-v , a phase III trial of dabrafenib plus trametinib versus vemurafenib monotherapy in previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF mutation ; and COLUMBUS Part 1 , a phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib monotherapy in patients with BRAF -mutant melanoma .
5-1	332-336	Four	abstract[21]	new[21]	coref	6-3[76_21]
5-2	337-342	phase	abstract[20]|abstract[21]	new[20]|new[21]	coref	5-11[0_20]
5-3	343-346	III	abstract[20]|abstract[21]	new[20]|new[21]	_	_
5-4	347-354	studies	abstract[21]	new[21]	_	_
5-5	355-359	were	_	_	_	_
5-6	360-370	identified	_	_	_	_
5-7	371-372	:	_	_	_	_
5-8	373-379	coBRIM	abstract	new	coref	6-7
5-9	380-381	,	_	_	_	_
5-10	382-383	a	event[25]	new[25]	_	_
5-11	384-389	phase	abstract|person[24]|event[25]	giv|giv[24]|new[25]	coref	5-34
5-12	390-393	III	person[24]|event[25]	giv[24]|new[25]	_	_
5-13	394-399	trial	event[25]	new[25]	_	_
5-14	400-402	of	event[25]	new[25]	_	_
5-15	403-414	cobimetinib	event[25]|substance|abstract[27]	new[25]|new|new[27]	coref|coref	10-21|21-3[239_27]
5-16	415-419	plus	event[25]|abstract[27]	new[25]|new[27]	_	_
5-17	420-431	vemurafenib	event[25]|abstract[27]|person[28]	new[25]|new[27]|new[28]	coref	5-19[0_28]
5-18	432-438	versus	event[25]|abstract[27]|person[28]	new[25]|new[27]|new[28]	_	_
5-19	439-450	vemurafenib	event[25]|abstract[27]|person[28]|person|abstract[30]	new[25]|new[27]|new[28]|giv|new[30]	coref|coref	5-42[40_30]|5-75
5-20	451-462	monotherapy	event[25]|abstract[27]|person[28]|abstract[30]	new[25]|new[27]|new[28]|new[30]	_	_
5-21	463-465	in	event[25]|abstract[27]|person[28]|abstract[30]	new[25]|new[27]|new[28]|new[30]	_	_
5-22	466-476	previously	event[25]|abstract[27]|person[28]|abstract[30]|person[31]	new[25]|new[27]|new[28]|new[30]|new[31]	coref	5-45[41_31]
5-23	477-486	untreated	event[25]|abstract[27]|person[28]|abstract[30]|person[31]	new[25]|new[27]|new[28]|new[30]|new[31]	_	_
5-24	487-495	patients	event[25]|abstract[27]|person[28]|abstract[30]|person[31]	new[25]|new[27]|new[28]|new[30]|new[31]	_	_
5-25	496-500	with	event[25]|abstract[27]|person[28]|abstract[30]|person[31]	new[25]|new[27]|new[28]|new[30]|new[31]	_	_
5-26	501-509	advanced	event[25]|abstract[27]|person[28]|abstract[30]|person[31]|abstract[33]	new[25]|new[27]|new[28]|new[30]|new[31]|giv[33]	coref	5-49[46_33]
5-27	510-514	BRAF	event[25]|abstract[27]|person[28]|abstract[30]|person[31]|abstract|abstract[33]	new[25]|new[27]|new[28]|new[30]|new[31]|giv|giv[33]	_	_
5-28	515-522	-mutant	event[25]|abstract[27]|person[28]|abstract[30]|person[31]|abstract[33]	new[25]|new[27]|new[28]|new[30]|new[31]|giv[33]	_	_
5-29	523-531	melanoma	event[25]|abstract[27]|person[28]|abstract[30]|person[31]|abstract[33]	new[25]|new[27]|new[28]|new[30]|new[31]|giv[33]	_	_
5-30	532-533	;	_	_	_	_
5-31	534-541	COMBI-d	abstract	new	coref	7-2[89_0]
5-32	542-543	,	_	_	_	_
5-33	544-545	a	event[36]	new[36]	_	_
5-34	546-551	phase	abstract|event[36]	giv|new[36]	coref	5-67
5-35	552-555	III	event[36]	new[36]	_	_
5-36	556-561	trial	event[36]	new[36]	_	_
5-37	562-564	of	event[36]	new[36]	_	_
5-38	565-575	dabrafenib	event[36]|animal	new[36]|new	coref	5-42
5-39	576-579	and	event[36]	new[36]	_	_
5-40	580-590	trametinib	event[36]|object	new[36]|new	coref	5-73[53_0]
5-41	591-597	versus	event[36]	new[36]	_	_
5-42	598-608	dabrafenib	event[36]|animal|abstract[40]	new[36]|giv|giv[40]	coref|coref	5-71|5-75[55_40]
5-43	609-620	monotherapy	event[36]|abstract[40]	new[36]|giv[40]	_	_
5-44	621-623	in	event[36]|abstract[40]	new[36]|giv[40]	_	_
5-45	624-634	previously	event[36]|abstract[40]|person[41]	new[36]|giv[40]|giv[41]	coref	5-78[56_41]
5-46	635-644	untreated	event[36]|abstract[40]|person[41]	new[36]|giv[40]|giv[41]	_	_
5-47	645-653	patients	event[36]|abstract[40]|person[41]	new[36]|giv[40]|giv[41]	_	_
5-48	654-658	with	event[36]|abstract[40]|person[41]	new[36]|giv[40]|giv[41]	_	_
5-49	659-671	unresectable	event[36]|abstract[40]|person[41]|abstract[46]	new[36]|giv[40]|giv[41]|giv[46]	coref	5-82[61_46]
5-50	672-677	stage	event[36]|abstract[40]|person[41]|abstract|abstract[43]|abstract[44]|abstract[46]	new[36]|giv[40]|giv[41]|new|new[43]|new[44]|giv[46]	coref|coref|coref	5-83|5-83[58_43]|5-83[59_44]
5-51	678-682	IIIC	event[36]|abstract[40]|person[41]|abstract[43]|abstract[44]|abstract[46]	new[36]|giv[40]|giv[41]|new[43]|new[44]|giv[46]	_	_
5-52	683-685	or	event[36]|abstract[40]|person[41]|abstract[44]|abstract[46]	new[36]|giv[40]|giv[41]|new[44]|giv[46]	_	_
5-53	686-691	stage	event[36]|abstract[40]|person[41]|abstract[44]|place[45]|abstract[46]	new[36]|giv[40]|giv[41]|new[44]|new[45]|giv[46]	coref	5-86[0_45]
5-54	692-694	IV	event[36]|abstract[40]|person[41]|abstract[44]|place[45]|abstract[46]	new[36]|giv[40]|giv[41]|new[44]|new[45]|giv[46]	_	_
5-55	695-703	melanoma	event[36]|abstract[40]|person[41]|abstract[46]	new[36]|giv[40]|giv[41]|giv[46]	_	_
5-56	704-708	with	event[36]|abstract[40]|person[41]|abstract[46]	new[36]|giv[40]|giv[41]|giv[46]	_	_
5-57	709-710	a	event[36]|abstract[40]|person[41]|abstract[46]|abstract[49]	new[36]|giv[40]|giv[41]|giv[46]|new[49]	coref	5-89[63_49]
5-58	711-715	BRAF	event[36]|abstract[40]|person[41]|abstract[46]|person|abstract[49]	new[36]|giv[40]|giv[41]|giv[46]|new|new[49]	coref	5-89
5-59	716-721	V600E	event[36]|abstract[40]|person[41]|abstract[46]|abstract[49]	new[36]|giv[40]|giv[41]|giv[46]|new[49]	_	_
5-60	722-724	or	event[36]|abstract[40]|person[41]|abstract[46]|abstract[49]	new[36]|giv[40]|giv[41]|giv[46]|new[49]	_	_
5-61	725-730	V600K	event[36]|abstract[40]|person[41]|abstract[46]|person|abstract[49]	new[36]|giv[40]|giv[41]|giv[46]|new|new[49]	_	_
5-62	731-739	mutation	event[36]|abstract[40]|person[41]|abstract[46]|abstract[49]	new[36]|giv[40]|giv[41]|giv[46]|new[49]	_	_
5-63	740-741	;	_	_	_	_
5-64	742-749	COMBI-v	abstract	new	coref	6-9
5-65	750-751	,	_	_	_	_
5-66	752-753	a	_	_	_	_
5-67	754-759	phase	abstract	giv	coref	5-98[65_0]
5-68	760-763	III	_	_	_	_
5-69	764-769	trial	_	_	_	_
5-70	770-772	of	_	_	_	_
5-71	773-783	dabrafenib	animal	giv	coref	10-25
5-72	784-788	plus	_	_	_	_
5-73	789-799	trametinib	object[53]	giv[53]	coref	10-27[0_53]
5-74	800-806	versus	object[53]	giv[53]	_	_
5-75	807-818	vemurafenib	object[53]|person|abstract[55]	giv[53]|giv|giv[55]	coref|coref	5-106|5-108[71_55]
5-76	819-830	monotherapy	object[53]|abstract[55]	giv[53]|giv[55]	_	_
5-77	831-833	in	_	_	_	_
5-78	834-844	previously	person[56]	giv[56]	coref	5-111[72_56]
5-79	845-854	untreated	person[56]	giv[56]	_	_
5-80	855-863	patients	person[56]	giv[56]	_	_
5-81	864-868	with	person[56]	giv[56]	_	_
5-82	869-881	unresectable	person[56]|abstract[61]	giv[56]|giv[61]	coref	5-113[74_61]
5-83	882-887	stage	person[56]|abstract|abstract[58]|abstract[59]|abstract[61]	giv[56]|giv|giv[58]|giv[59]|giv[61]	_	_
5-84	888-892	IIIC	person[56]|abstract[58]|abstract[59]|abstract[61]	giv[56]|giv[58]|giv[59]|giv[61]	_	_
5-85	893-895	or	person[56]|abstract[59]|abstract[61]	giv[56]|giv[59]|giv[61]	_	_
5-86	896-898	IV	person[56]|abstract[59]|place|abstract[61]	giv[56]|giv[59]|giv|giv[61]	_	_
5-87	899-907	melanoma	person[56]|abstract[61]	giv[56]|giv[61]	_	_
5-88	908-912	with	person[56]|abstract[61]	giv[56]|giv[61]	_	_
5-89	913-917	BRAF	person[56]|abstract[61]|person|abstract[63]	giv[56]|giv[61]|giv|giv[63]	coref	5-113
5-90	918-926	mutation	person[56]|abstract[61]|abstract[63]	giv[56]|giv[61]|giv[63]	_	_
5-91	927-928	;	_	_	_	_
5-92	929-932	and	_	_	_	_
5-93	933-941	COLUMBUS	abstract[64]	new[64]	coref	6-12[80_64]
5-94	942-946	Part	abstract[64]	new[64]	_	_
5-95	947-948	1	abstract[64]	new[64]	_	_
5-96	949-950	,	_	_	_	_
5-97	951-952	a	event[66]	new[66]	coref	12-5[155_66]
5-98	953-958	phase	abstract[65]|event[66]	giv[65]|new[66]	coref	9-9[0_65]
5-99	959-962	III	abstract[65]|event[66]	giv[65]|new[66]	_	_
5-100	963-968	trial	event[66]	new[66]	_	_
5-101	969-971	of	event[66]	new[66]	_	_
5-102	972-983	encorafenib	event[66]|abstract	new[66]|new	coref	5-108
5-103	984-988	plus	event[66]	new[66]	_	_
5-104	989-1000	binimetinib	event[66]|abstract[68]	new[66]|new[68]	coref	10-32[0_68]
5-105	1001-1007	versus	event[66]|abstract[68]	new[66]|new[68]	_	_
5-106	1008-1019	vemurafenib	event[66]|abstract[68]|person	new[66]|new[68]|giv	coref	6-18
5-107	1020-1022	or	event[66]	new[66]	_	_
5-108	1023-1034	encorafenib	event[66]|abstract|abstract[71]	new[66]|giv|giv[71]	coref	10-29
5-109	1035-1046	monotherapy	event[66]|abstract[71]	new[66]|giv[71]	_	_
5-110	1047-1049	in	event[66]	new[66]	_	_
5-111	1050-1058	patients	event[66]|person[72]	new[66]|giv[72]	_	_
5-112	1059-1063	with	event[66]|person[72]	new[66]|giv[72]	_	_
5-113	1064-1068	BRAF	event[66]|person[72]|person|abstract[74]	new[66]|giv[72]|giv|giv[74]	_	_
5-114	1069-1076	-mutant	event[66]|person[72]|abstract[74]	new[66]|giv[72]|giv[74]	_	_
5-115	1077-1085	melanoma	event[66]|person[72]|abstract[74]	new[66]|giv[72]|giv[74]	_	_
5-116	1086-1087	.	_	_	_	_

#Text=Three of the identified studies ( coBRIM , COMBI-v , and COLUMBUS Part 1 ) , had vemurafenib 960 mg twice daily ( BID ) as a control arm , and were the chief sources of data for the comparisons presented here .
6-1	1088-1093	Three	abstract[75]	new[75]	_	_
6-2	1094-1096	of	abstract[75]	new[75]	_	_
6-3	1097-1100	the	abstract[75]|abstract[76]	new[75]|giv[76]	appos	6-7[78_76]
6-4	1101-1111	identified	abstract[75]|abstract[76]	new[75]|giv[76]	_	_
6-5	1112-1119	studies	abstract[75]|abstract[76]	new[75]|giv[76]	_	_
6-6	1120-1121	(	_	_	_	_
6-7	1122-1128	coBRIM	abstract|abstract[78]	giv|giv[78]	coref|coref	11-6|14-8[178_78]
6-8	1129-1130	,	abstract[78]	giv[78]	_	_
6-9	1131-1138	COMBI-v	abstract[78]|abstract	giv[78]|giv	coref	8-19
6-10	1139-1140	,	abstract[78]	giv[78]	_	_
6-11	1141-1144	and	abstract[78]	giv[78]	_	_
6-12	1145-1153	COLUMBUS	abstract[78]|abstract[80]	giv[78]|giv[80]	_	_
6-13	1154-1158	Part	abstract[78]|abstract[80]	giv[78]|giv[80]	_	_
6-14	1159-1160	1	abstract[78]|abstract[80]	giv[78]|giv[80]	_	_
6-15	1161-1162	)	_	_	_	_
6-16	1163-1164	,	_	_	_	_
6-17	1165-1168	had	_	_	_	_
6-18	1169-1180	vemurafenib	person|substance[82]	giv|new[82]	coref	7-32
6-19	1181-1184	960	substance[82]	new[82]	_	_
6-20	1185-1187	mg	substance[82]	new[82]	_	_
6-21	1188-1193	twice	_	_	_	_
6-22	1194-1199	daily	_	_	_	_
6-23	1200-1201	(	_	_	_	_
6-24	1202-1205	BID	abstract	new	_	_
6-25	1206-1207	)	_	_	_	_
6-26	1208-1210	as	_	_	_	_
6-27	1211-1212	a	object[85]	new[85]	coref	7-31[99_85]
6-28	1213-1220	control	abstract|object[85]	new|new[85]	coref	7-33
6-29	1221-1224	arm	object[85]	new[85]	_	_
6-30	1225-1226	,	_	_	_	_
6-31	1227-1230	and	_	_	_	_
6-32	1231-1235	were	_	_	_	_
6-33	1236-1239	the	abstract[86]	new[86]	coref	11-1[122_86]
6-34	1240-1245	chief	abstract[86]	new[86]	_	_
6-35	1246-1253	sources	abstract[86]	new[86]	_	_
6-36	1254-1256	of	abstract[86]	new[86]	_	_
6-37	1257-1261	data	abstract[86]|abstract	new[86]|giv	coref	10-34[120_0]
6-38	1262-1265	for	abstract[86]	new[86]	_	_
6-39	1266-1269	the	abstract[86]|abstract[88]	new[86]|new[88]	coref	15-1[186_88]
6-40	1270-1281	comparisons	abstract[86]|abstract[88]	new[86]|new[88]	_	_
6-41	1282-1291	presented	abstract[86]|abstract[88]	new[86]|new[88]	_	_
6-42	1292-1296	here	abstract[86]|abstract[88]	new[86]|new[88]	_	_
6-43	1297-1298	.	_	_	_	_

#Text=Although the COMBI-d was identified as part of the initial literature search , it was not included in the efficacy comparison of the cross-trial comparison due to the lack of a vemurafenib control arm .
7-1	1299-1307	Although	_	_	_	_
7-2	1308-1311	the	abstract[89]	giv[89]	ana	7-14[0_89]
7-3	1312-1319	COMBI-d	abstract[89]	giv[89]	_	_
7-4	1320-1323	was	_	_	_	_
7-5	1324-1334	identified	_	_	_	_
7-6	1335-1337	as	_	_	_	_
7-7	1338-1342	part	_	_	_	_
7-8	1343-1345	of	_	_	_	_
7-9	1346-1349	the	event[91]	giv[91]	_	_
7-10	1350-1357	initial	event[91]	giv[91]	_	_
7-11	1358-1368	literature	abstract|event[91]	giv|giv[91]	_	_
7-12	1369-1375	search	event[91]	giv[91]	_	_
7-13	1376-1377	,	_	_	_	_
7-14	1378-1380	it	abstract	giv	coref	8-12
7-15	1381-1384	was	_	_	_	_
7-16	1385-1388	not	_	_	_	_
7-17	1389-1397	included	_	_	_	_
7-18	1398-1400	in	_	_	_	_
7-19	1401-1404	the	abstract[94]	new[94]	coref	7-23[95_94]
7-20	1405-1413	efficacy	abstract|abstract[94]	giv|new[94]	coref	13-2
7-21	1414-1424	comparison	abstract[94]	new[94]	_	_
7-22	1425-1427	of	abstract[94]	new[94]	_	_
7-23	1428-1431	the	abstract[94]|abstract[95]	new[94]|giv[95]	coref	10-7[110_95]
7-24	1432-1443	cross-trial	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
7-25	1444-1454	comparison	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
7-26	1455-1458	due	_	_	_	_
7-27	1459-1461	to	_	_	_	_
7-28	1462-1465	the	abstract[96]	new[96]	ana	8-1[0_96]
7-29	1466-1470	lack	abstract[96]	new[96]	_	_
7-30	1471-1473	of	abstract[96]	new[96]	_	_
7-31	1474-1475	a	abstract[96]|object[99]	new[96]|giv[99]	_	_
7-32	1476-1487	vemurafenib	abstract[96]|person|object[99]	new[96]|giv|giv[99]	coref	21-5
7-33	1488-1495	control	abstract[96]|abstract|object[99]	new[96]|giv|giv[99]	_	_
7-34	1496-1499	arm	abstract[96]|object[99]	new[96]|giv[99]	_	_
7-35	1500-1501	.	_	_	_	_

#Text=It should be noted , however , that the outcomes in COMBI-d were substantially similar to those in COMBI-v .
8-1	1502-1504	It	abstract	giv	ana	8-17[103_0]
8-2	1505-1511	should	_	_	_	_
8-3	1512-1514	be	_	_	_	_
8-4	1515-1520	noted	_	_	_	_
8-5	1521-1522	,	_	_	_	_
8-6	1523-1530	however	_	_	_	_
8-7	1531-1532	,	_	_	_	_
8-8	1533-1537	that	_	_	_	_
8-9	1538-1541	the	abstract[101]	new[101]	coref	13-1[163_101]
8-10	1542-1550	outcomes	abstract[101]	new[101]	_	_
8-11	1551-1553	in	abstract[101]	new[101]	_	_
8-12	1554-1561	COMBI-d	abstract[101]|abstract	new[101]|giv	coref	20-16
8-13	1562-1566	were	_	_	_	_
8-14	1567-1580	substantially	_	_	_	_
8-15	1581-1588	similar	_	_	_	_
8-16	1589-1591	to	_	_	_	_
8-17	1592-1597	those	abstract[103]	giv[103]	_	_
8-18	1598-1600	in	abstract[103]	giv[103]	_	_
8-19	1601-1608	COMBI-v	abstract[103]|abstract	giv[103]|giv	coref	11-8
8-20	1609-1610	.	_	_	_	_

#Text=The key design features of the three included phase III trials are summarized in Table 5 .
9-1	1611-1614	The	abstract[106]	new[106]	_	_
9-2	1615-1618	key	abstract[106]	new[106]	_	_
9-3	1619-1625	design	abstract|abstract[106]	new|new[106]	_	_
9-4	1626-1634	features	abstract[106]	new[106]	_	_
9-5	1635-1637	of	abstract[106]	new[106]	_	_
9-6	1638-1641	the	abstract[106]|event[108]	new[106]|new[108]	coref	11-5[125_108]
9-7	1642-1647	three	abstract[106]|event[108]	new[106]|new[108]	_	_
9-8	1648-1656	included	abstract[106]|event[108]	new[106]|new[108]	_	_
9-9	1657-1662	phase	abstract[106]|abstract|event[108]	new[106]|giv|new[108]	_	_
9-10	1663-1666	III	abstract[106]|event[108]	new[106]|new[108]	_	_
9-11	1667-1673	trials	abstract[106]|event[108]	new[106]|new[108]	_	_
9-12	1674-1677	are	_	_	_	_
9-13	1678-1688	summarized	_	_	_	_
9-14	1689-1691	in	_	_	_	_
9-15	1692-1697	Table	abstract[109]	giv[109]	coref	11-46[141_109]
9-16	1698-1699	5	abstract[109]	giv[109]	_	_
9-17	1700-1701	.	_	_	_	_

#Text=To assist with the completeness of the cross-trial comparison , medical information requests were made to the registered sponsor of cobimetinib , vemurafenib , dabrafenib , trametinib , encorafenib , or binimetinib if any missing data were identified .
10-1	1702-1704	To	_	_	_	_
10-2	1705-1711	assist	_	_	_	_
10-3	1712-1716	with	_	_	_	_
10-4	1717-1720	the	_	_	_	_
10-5	1721-1733	completeness	_	_	_	_
10-6	1734-1736	of	_	_	_	_
10-7	1737-1740	the	abstract[110]	giv[110]	_	_
10-8	1741-1752	cross-trial	abstract[110]	giv[110]	_	_
10-9	1753-1763	comparison	abstract[110]	giv[110]	_	_
10-10	1764-1765	,	_	_	_	_
10-11	1766-1773	medical	abstract[112]	new[112]	_	_
10-12	1774-1785	information	abstract|abstract[112]	new|new[112]	coref	11-39[140_0]
10-13	1786-1794	requests	abstract[112]	new[112]	_	_
10-14	1795-1799	were	_	_	_	_
10-15	1800-1804	made	_	_	_	_
10-16	1805-1807	to	_	_	_	_
10-17	1808-1811	the	person[113]	new[113]	_	_
10-18	1812-1822	registered	person[113]	new[113]	_	_
10-19	1823-1830	sponsor	person[113]	new[113]	_	_
10-20	1831-1833	of	person[113]	new[113]	_	_
10-21	1834-1845	cobimetinib	person[113]|substance	new[113]|giv	coref	21-3
10-22	1846-1847	,	person[113]	new[113]	_	_
10-23	1848-1859	vemurafenib	person[113]|abstract	new[113]|new	_	_
10-24	1860-1861	,	person[113]	new[113]	_	_
10-25	1862-1872	dabrafenib	person[113]|animal	new[113]|giv	coref	20-7[233_0]
10-26	1873-1874	,	person[113]	new[113]	_	_
10-27	1875-1885	trametinib	person[113]|object	new[113]|giv	coref	20-10
10-28	1886-1887	,	person[113]	new[113]	_	_
10-29	1888-1899	encorafenib	person[113]|abstract	new[113]|giv	coref	22-16[249_0]
10-30	1900-1901	,	person[113]	new[113]	_	_
10-31	1902-1904	or	person[113]	new[113]	_	_
10-32	1905-1916	binimetinib	person[113]|abstract	new[113]|giv	coref	22-19
10-33	1917-1919	if	_	_	_	_
10-34	1920-1923	any	abstract[120]	giv[120]	coref	11-2[0_120]
10-35	1924-1931	missing	abstract[120]	giv[120]	_	_
10-36	1932-1936	data	abstract[120]	giv[120]	_	_
10-37	1937-1941	were	_	_	_	_
10-38	1942-1952	identified	_	_	_	_
10-39	1953-1954	.	_	_	_	_

#Text=The data sources for the coBRIM and COMBI-v trials included primary and secondary publications of data , European public assessment reports ( EPAR ) , U.S. Food and Drug Administration ( FDA ) medical review documents , and the current U.S. prescribing information ( see Table S5 , which illustrates the data sources and cutoff dates for COMBI-v , coBRIM , and COLUMBUS trials ) .
11-1	1955-1958	The	abstract[122]	giv[122]	coref	11-51[144_122]
11-2	1959-1963	data	abstract|abstract[122]	giv|giv[122]	coref	11-16
11-3	1964-1971	sources	abstract[122]	giv[122]	_	_
11-4	1972-1975	for	abstract[122]	giv[122]	_	_
11-5	1976-1979	the	abstract[122]|event[125]	giv[122]|giv[125]	coref	11-58[151_125]
11-6	1980-1986	coBRIM	abstract[122]|abstract|event[125]	giv[122]|giv|giv[125]	coref	11-60
11-7	1987-1990	and	abstract[122]|event[125]	giv[122]|giv[125]	_	_
11-8	1991-1998	COMBI-v	abstract[122]|abstract|event[125]	giv[122]|giv|giv[125]	coref	11-58
11-9	1999-2005	trials	abstract[122]|event[125]	giv[122]|giv[125]	_	_
11-10	2006-2014	included	_	_	_	_
11-11	2015-2022	primary	organization[126]	new[126]	_	_
11-12	2023-2026	and	organization[126]	new[126]	_	_
11-13	2027-2036	secondary	organization[126]	new[126]	_	_
11-14	2037-2049	publications	organization[126]	new[126]	_	_
11-15	2050-2052	of	organization[126]	new[126]	_	_
11-16	2053-2057	data	organization[126]|abstract	new[126]|giv	coref	11-52
11-17	2058-2059	,	_	_	_	_
11-18	2060-2068	European	abstract[129]	new[129]	_	_
11-19	2069-2075	public	abstract[128]|abstract[129]	new[128]|new[129]	coref	13-22[173_128]
11-20	2076-2086	assessment	abstract[128]|abstract[129]	new[128]|new[129]	_	_
11-21	2087-2094	reports	abstract[129]	new[129]	_	_
11-22	2095-2096	(	_	_	_	_
11-23	2097-2101	EPAR	organization	new	_	_
11-24	2102-2103	)	_	_	_	_
11-25	2104-2105	,	_	_	_	_
11-26	2106-2110	U.S.	place|organization[134]|object[137]	new|new[134]|new[137]	appos|coref	11-32[0_134]|11-41
11-27	2111-2115	Food	object|organization[134]|object[137]	new|new[134]|new[137]	_	_
11-28	2116-2119	and	organization[134]|object[137]	new[134]|new[137]	_	_
11-29	2120-2124	Drug	substance|organization[134]|object[137]	new|new[134]|new[137]	coref	15-22
11-30	2125-2139	Administration	organization[134]|object[137]	new[134]|new[137]	_	_
11-31	2140-2141	(	object[137]	new[137]	_	_
11-32	2142-2145	FDA	organization|object[137]	giv|new[137]	_	_
11-33	2146-2147	)	object[137]	new[137]	_	_
11-34	2148-2155	medical	abstract[136]|object[137]	new[136]|new[137]	_	_
11-35	2156-2162	review	abstract[136]|object[137]	new[136]|new[137]	_	_
11-36	2163-2172	documents	object[137]	new[137]	_	_
11-37	2173-2174	,	_	_	_	_
11-38	2175-2178	and	_	_	_	_
11-39	2179-2182	the	abstract[140]	giv[140]	coref	12-13[158_140]
11-40	2183-2190	current	abstract[140]	giv[140]	_	_
11-41	2191-2195	U.S.	place|abstract[140]	giv|giv[140]	coref	19-13
11-42	2196-2207	prescribing	person|abstract[140]	new|giv[140]	coref	12-14
11-43	2208-2219	information	abstract[140]	giv[140]	_	_
11-44	2220-2221	(	_	_	_	_
11-45	2222-2225	see	_	_	_	_
11-46	2226-2231	Table	abstract[141]	giv[141]	_	_
11-47	2232-2234	S5	abstract[141]|abstract	giv[141]|new	_	_
11-48	2235-2236	,	abstract[141]	giv[141]	_	_
11-49	2237-2242	which	abstract[141]	giv[141]	_	_
11-50	2243-2254	illustrates	abstract[141]	giv[141]	_	_
11-51	2255-2258	the	abstract[141]|abstract[144]|abstract[145]	giv[141]|giv[144]|giv[145]	coref|coref	11-51[145_144]|12-1[153_145]
11-52	2259-2263	data	abstract[141]|abstract|abstract[144]|abstract[145]	giv[141]|giv|giv[144]|giv[145]	coref	12-2
11-53	2264-2271	sources	abstract[141]|abstract[144]|abstract[145]	giv[141]|giv[144]|giv[145]	_	_
11-54	2272-2275	and	abstract[141]|abstract[145]	giv[141]|giv[145]	_	_
11-55	2276-2282	cutoff	abstract[141]|abstract[145]|abstract|time[147]	giv[141]|giv[145]|new|new[147]	_	_
11-56	2283-2288	dates	abstract[141]|abstract[145]|time[147]	giv[141]|giv[145]|new[147]	_	_
11-57	2289-2292	for	abstract[141]|abstract[145]|time[147]	giv[141]|giv[145]|new[147]	_	_
11-58	2293-2300	COMBI-v	abstract[141]|abstract[145]|time[147]|abstract|event[151]	giv[141]|giv[145]|new[147]|giv|giv[151]	coref|coref	18-4|18-1[220_151]
11-59	2301-2302	,	abstract[141]|abstract[145]|time[147]|event[151]	giv[141]|giv[145]|new[147]|giv[151]	_	_
11-60	2303-2309	coBRIM	abstract[141]|abstract[145]|time[147]|abstract|event[151]	giv[141]|giv[145]|new[147]|giv|giv[151]	coref	18-2
11-61	2310-2311	,	abstract[141]|abstract[145]|time[147]|event[151]	giv[141]|giv[145]|new[147]|giv[151]	_	_
11-62	2312-2315	and	abstract[141]|abstract[145]|time[147]|event[151]	giv[141]|giv[145]|new[147]|giv[151]	_	_
11-63	2316-2324	COLUMBUS	abstract[141]|abstract[145]|time[147]|place|event[151]	giv[141]|giv[145]|new[147]|new|giv[151]	coref	12-6
11-64	2325-2331	trials	abstract[141]|abstract[145]|time[147]|event[151]	giv[141]|giv[145]|new[147]|giv[151]	_	_
11-65	2332-2333	)	_	_	_	_
11-66	2334-2335	.	_	_	_	_

#Text=The data sources for the COLUMBUS trial include a primary publication , U.S. prescribing information , and Array BioPharma data on file .
12-1	2336-2339	The	abstract[153]	giv[153]	_	_
12-2	2340-2344	data	abstract|abstract[153]	giv|giv[153]	coref	12-18[160_0]
12-3	2345-2352	sources	abstract[153]	giv[153]	_	_
12-4	2353-2356	for	abstract[153]	giv[153]	_	_
12-5	2357-2360	the	abstract[153]|event[155]	giv[153]|giv[155]	coref	15-7[187_155]
12-6	2361-2369	COLUMBUS	abstract[153]|place|event[155]	giv[153]|giv|giv[155]	coref	18-12
12-7	2370-2375	trial	abstract[153]|event[155]	giv[153]|giv[155]	_	_
12-8	2376-2383	include	_	_	_	_
12-9	2384-2385	a	abstract[156]	new[156]	_	_
12-10	2386-2393	primary	abstract[156]	new[156]	_	_
12-11	2394-2405	publication	abstract[156]	new[156]	_	_
12-12	2406-2407	,	_	_	_	_
12-13	2408-2412	U.S.	abstract[158]	giv[158]	_	_
12-14	2413-2424	prescribing	person|abstract[158]	giv|giv[158]	_	_
12-15	2425-2436	information	abstract[158]	giv[158]	_	_
12-16	2437-2438	,	_	_	_	_
12-17	2439-2442	and	_	_	_	_
12-18	2443-2448	Array	organization[159]|abstract[160]	new[159]|giv[160]	coref	15-40[0_160]
12-19	2449-2458	BioPharma	organization[159]|abstract[160]	new[159]|giv[160]	_	_
12-20	2459-2463	data	abstract[160]	giv[160]	_	_
12-21	2464-2466	on	abstract[160]	giv[160]	_	_
12-22	2467-2471	file	abstract[160]|object	giv[160]|new	_	_
12-23	2472-2473	.	_	_	_	_

#Text=The efficacy outcomes presented are PFS , objective response rate ( ORR ) , duration of response ( DOR ) per investigator assessment , and OS .
13-1	2474-2477	The	abstract[163]	giv[163]	coref	13-6[0_163]
13-2	2478-2486	efficacy	abstract|abstract[163]	giv|giv[163]	_	_
13-3	2487-2495	outcomes	abstract[163]	giv[163]	_	_
13-4	2496-2505	presented	abstract[163]	giv[163]	_	_
13-5	2506-2509	are	_	_	_	_
13-6	2510-2513	PFS	abstract|abstract[165]	giv|giv[165]	coref	13-6[165_0]
13-7	2514-2515	,	abstract[165]	giv[165]	_	_
13-8	2516-2525	objective	abstract[165]|abstract[167]	giv[165]|new[167]	appos	13-12[0_167]
13-9	2526-2534	response	abstract[165]|abstract|abstract[167]	giv[165]|new|new[167]	coref	13-17
13-10	2535-2539	rate	abstract[165]|abstract[167]	giv[165]|new[167]	_	_
13-11	2540-2541	(	abstract[165]	giv[165]	_	_
13-12	2542-2545	ORR	abstract[165]|abstract	giv[165]|giv	_	_
13-13	2546-2547	)	abstract[165]	giv[165]	_	_
13-14	2548-2549	,	abstract[165]	giv[165]	_	_
13-15	2550-2558	duration	abstract[165]|time[169]	giv[165]|new[169]	_	_
13-16	2559-2561	of	abstract[165]|time[169]	giv[165]|new[169]	_	_
13-17	2562-2570	response	abstract[165]|time[169]|abstract	giv[165]|new[169]|giv	coref	14-4[177_0]
13-18	2571-2572	(	abstract[165]	giv[165]	_	_
13-19	2573-2576	DOR	abstract[165]|abstract	giv[165]|new	_	_
13-20	2577-2578	)	abstract[165]	giv[165]	_	_
13-21	2579-2582	per	abstract[165]	giv[165]	_	_
13-22	2583-2595	investigator	abstract[165]|person|abstract[173]	giv[165]|new|giv[173]	_	_
13-23	2596-2606	assessment	abstract[165]|abstract[173]	giv[165]|giv[173]	_	_
13-24	2607-2608	,	abstract[165]	giv[165]	_	_
13-25	2609-2612	and	abstract[165]	giv[165]	_	_
13-26	2613-2615	OS	abstract[165]|abstract	giv[165]|new	_	_
13-27	2616-2617	.	_	_	_	_

#Text=The assessments of the tumor response across the studies were performed using Response Evaluation Criteria in Solid Tumors ( RECIST ) version 1.1 .
14-1	2618-2621	The	abstract[175]	new[175]	_	_
14-2	2622-2633	assessments	abstract[175]	new[175]	_	_
14-3	2634-2636	of	abstract[175]	new[175]	_	_
14-4	2637-2640	the	abstract[175]|abstract[177]	new[175]|giv[177]	coref	14-13[0_177]
14-5	2641-2646	tumor	abstract[175]|abstract|abstract[177]	new[175]|new|giv[177]	_	_
14-6	2647-2655	response	abstract[175]|abstract[177]	new[175]|giv[177]	_	_
14-7	2656-2662	across	abstract[175]	new[175]	_	_
14-8	2663-2666	the	abstract[175]|abstract[178]	new[175]|giv[178]	coref	17-1[210_178]
14-9	2667-2674	studies	abstract[175]|abstract[178]	new[175]|giv[178]	_	_
14-10	2675-2679	were	_	_	_	_
14-11	2680-2689	performed	_	_	_	_
14-12	2690-2695	using	_	_	_	_
14-13	2696-2704	Response	abstract|abstract[181]	giv|new[181]	appos	14-20[0_181]
14-14	2705-2715	Evaluation	abstract|abstract[181]	new|new[181]	_	_
14-15	2716-2724	Criteria	abstract[181]	new[181]	_	_
14-16	2725-2727	in	abstract[181]	new[181]	_	_
14-17	2728-2733	Solid	abstract[181]|abstract[182]	new[181]|new[182]	_	_
14-18	2734-2740	Tumors	abstract[181]|abstract[182]	new[181]|new[182]	_	_
14-19	2741-2742	(	_	_	_	_
14-20	2743-2749	RECIST	abstract	giv	appos	14-22[184_0]
14-21	2750-2751	)	_	_	_	_
14-22	2752-2759	version	abstract[184]	giv[184]	coref	17-4[214_184]
14-23	2760-2763	1.1	abstract[184]	giv[184]	_	_
14-24	2764-2765	.	_	_	_	_

#Text=The safety comparisons were made using the adverse event ( any untoward medical occurrence regardless of causal relationship ) and adverse drug reaction ( noxious and unintended responses with at least a reasonable possibility of a causal relationship ) data .
15-1	2766-2769	The	abstract[186]	giv[186]	_	_
15-2	2770-2776	safety	abstract|abstract[186]	giv|giv[186]	_	_
15-3	2777-2788	comparisons	abstract[186]	giv[186]	_	_
15-4	2789-2793	were	_	_	_	_
15-5	2794-2798	made	_	_	_	_
15-6	2799-2804	using	_	_	_	_
15-7	2805-2808	the	event[187]	giv[187]	appos	15-11[188_187]
15-8	2809-2816	adverse	event[187]	giv[187]	_	_
15-9	2817-2822	event	event[187]	giv[187]	_	_
15-10	2823-2824	(	_	_	_	_
15-11	2825-2828	any	event[188]	giv[188]	coref	16-2[196_188]
15-12	2829-2837	untoward	event[188]	giv[188]	_	_
15-13	2838-2845	medical	event[188]	giv[188]	_	_
15-14	2846-2856	occurrence	event[188]	giv[188]	_	_
15-15	2857-2867	regardless	event[188]	giv[188]	_	_
15-16	2868-2870	of	_	_	_	_
15-17	2871-2877	causal	abstract[189]	new[189]	coref	15-36[194_189]
15-18	2878-2890	relationship	abstract[189]	new[189]	_	_
15-19	2891-2892	)	_	_	_	_
15-20	2893-2896	and	_	_	_	_
15-21	2897-2904	adverse	event[191]	new[191]	_	_
15-22	2905-2909	drug	substance|event[191]	giv|new[191]	coref	19-8
15-23	2910-2918	reaction	event[191]	new[191]	_	_
15-24	2919-2920	(	_	_	_	_
15-25	2921-2928	noxious	abstract[192]	new[192]	_	_
15-26	2929-2932	and	abstract[192]	new[192]	_	_
15-27	2933-2943	unintended	abstract[192]	new[192]	_	_
15-28	2944-2953	responses	abstract[192]	new[192]	_	_
15-29	2954-2958	with	abstract[192]	new[192]	_	_
15-30	2959-2961	at	abstract[192]	new[192]	_	_
15-31	2962-2967	least	abstract[192]|abstract[193]	new[192]|new[193]	_	_
15-32	2968-2969	a	abstract[192]|abstract[193]	new[192]|new[193]	_	_
15-33	2970-2980	reasonable	abstract[192]|abstract[193]	new[192]|new[193]	_	_
15-34	2981-2992	possibility	abstract[192]|abstract[193]	new[192]|new[193]	_	_
15-35	2993-2995	of	abstract[192]|abstract[193]	new[192]|new[193]	_	_
15-36	2996-2997	a	abstract[192]|abstract[193]|abstract[194]	new[192]|new[193]|giv[194]	_	_
15-37	2998-3004	causal	abstract[192]|abstract[193]|abstract[194]	new[192]|new[193]|giv[194]	_	_
15-38	3005-3017	relationship	abstract[192]|abstract[193]|abstract[194]	new[192]|new[193]|giv[194]	_	_
15-39	3018-3019	)	_	_	_	_
15-40	3020-3024	data	abstract	giv	coref	16-1[197_0]
15-41	3025-3026	.	_	_	_	_

#Text=The adverse event data included the overall summaries ( comprising all-grade , serious , and grade 3/4 AEs , and AEs leading to death , dose interruption/modification , and discontinuation ) and the incidence of specific all-grade and grade 3/4 AEs by individual preferred terms per the MedDRA dictionary .
16-1	3027-3030	The	abstract[197]	giv[197]	coref	19-5[226_197]
16-2	3031-3038	adverse	event[196]|abstract[197]	giv[196]|giv[197]	coref	18-11[223_196]
16-3	3039-3044	event	event[196]|abstract[197]	giv[196]|giv[197]	_	_
16-4	3045-3049	data	abstract[197]	giv[197]	_	_
16-5	3050-3058	included	_	_	_	_
16-6	3059-3062	the	abstract[198]	new[198]	_	_
16-7	3063-3070	overall	abstract[198]	new[198]	_	_
16-8	3071-3080	summaries	abstract[198]	new[198]	_	_
16-9	3081-3082	(	abstract[198]	new[198]	_	_
16-10	3083-3093	comprising	abstract[198]	new[198]	_	_
16-11	3094-3103	all-grade	abstract[198]|abstract[200]	new[198]|new[200]	coref	16-36[206_200]
16-12	3104-3105	,	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-13	3106-3113	serious	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-14	3114-3115	,	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-15	3116-3119	and	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-16	3120-3125	grade	abstract[198]|abstract|abstract[200]	new[198]|new|new[200]	_	_
16-17	3126-3129	3/4	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-18	3130-3133	AEs	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-19	3134-3135	,	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-20	3136-3139	and	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-21	3140-3143	AEs	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-22	3144-3151	leading	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-23	3152-3154	to	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-24	3155-3160	death	abstract[198]|abstract[200]|event	new[198]|new[200]|new	_	_
16-25	3161-3162	,	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-26	3163-3167	dose	abstract[198]|abstract[200]|abstract|event[203]	new[198]|new[200]|new|new[203]	_	_
16-27	3168-3193	interruption/modification	abstract[198]|abstract[200]|event[203]	new[198]|new[200]|new[203]	_	_
16-28	3194-3195	,	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-29	3196-3199	and	abstract[198]|abstract[200]	new[198]|new[200]	_	_
16-30	3200-3215	discontinuation	abstract[198]|abstract[200]|event	new[198]|new[200]|new	_	_
16-31	3216-3217	)	abstract[198]	new[198]	_	_
16-32	3218-3221	and	_	_	_	_
16-33	3222-3225	the	abstract[205]	new[205]	_	_
16-34	3226-3235	incidence	abstract[205]	new[205]	_	_
16-35	3236-3238	of	abstract[205]	new[205]	_	_
16-36	3239-3247	specific	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
16-37	3248-3257	all-grade	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
16-38	3258-3261	and	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
16-39	3262-3267	grade	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
16-40	3268-3271	3/4	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
16-41	3272-3275	AEs	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
16-42	3276-3278	by	abstract[205]	new[205]	_	_
16-43	3279-3289	individual	abstract[205]|abstract[207]	new[205]|new[207]	_	_
16-44	3290-3299	preferred	abstract[205]|abstract[207]	new[205]|new[207]	_	_
16-45	3300-3305	terms	abstract[205]|abstract[207]	new[205]|new[207]	_	_
16-46	3306-3309	per	abstract[205]|abstract[207]	new[205]|new[207]	_	_
16-47	3310-3313	the	abstract[205]|abstract[207]|abstract[209]	new[205]|new[207]|new[209]	_	_
16-48	3314-3320	MedDRA	abstract[205]|abstract[207]|person|abstract[209]	new[205]|new[207]|new|new[209]	_	_
16-49	3321-3331	dictionary	abstract[205]|abstract[207]|abstract[209]	new[205]|new[207]|new[209]	_	_
16-50	3332-3333	.	_	_	_	_

#Text=All studies utilized the National Cancer Institute ( NCI ) Common Terminology Criteria for Adverse Events ( CTCAE ) to assess severity .
17-1	3334-3337	All	abstract[210]	giv[210]	_	_
17-2	3338-3345	studies	abstract[210]	giv[210]	_	_
17-3	3346-3354	utilized	_	_	_	_
17-4	3355-3358	the	abstract[214]	giv[214]	_	_
17-5	3359-3367	National	organization[211]|abstract[214]	new[211]|giv[214]	appos	17-9[0_211]
17-6	3368-3374	Cancer	organization[211]|abstract[214]	new[211]|giv[214]	_	_
17-7	3375-3384	Institute	organization[211]|abstract[214]	new[211]|giv[214]	_	_
17-8	3385-3386	(	abstract[214]	giv[214]	_	_
17-9	3387-3390	NCI	organization|abstract[214]	giv|giv[214]	_	_
17-10	3391-3392	)	abstract[214]	giv[214]	_	_
17-11	3393-3399	Common	abstract[213]|abstract[214]	new[213]|giv[214]	_	_
17-12	3400-3411	Terminology	abstract[213]|abstract[214]	new[213]|giv[214]	_	_
17-13	3412-3420	Criteria	abstract[214]	giv[214]	_	_
17-14	3421-3424	for	abstract[214]	giv[214]	_	_
17-15	3425-3432	Adverse	abstract[214]|abstract[215]	giv[214]|new[215]	appos	17-18[0_215]
17-16	3433-3439	Events	abstract[214]|abstract[215]	giv[214]|new[215]	_	_
17-17	3440-3441	(	_	_	_	_
17-18	3442-3447	CTCAE	abstract	giv	_	_
17-19	3448-3449	)	_	_	_	_
17-20	3450-3452	to	_	_	_	_
17-21	3453-3459	assess	_	_	_	_
17-22	3460-3468	severity	abstract	new	_	_
17-23	3469-3470	.	_	_	_	_

#Text=The coBRIM and COMBI-v trials used version 4.0 , whereas the COLUMBUS trial used version 4.03 .
18-1	3471-3474	The	event[220]	giv[220]	_	_
18-2	3475-3481	coBRIM	abstract|event[220]	giv|giv[220]	coref	21-9
18-3	3482-3485	and	event[220]	giv[220]	_	_
18-4	3486-3493	COMBI-v	abstract|event[220]	giv|giv[220]	_	_
18-5	3494-3500	trials	event[220]	giv[220]	_	_
18-6	3501-3505	used	_	_	_	_
18-7	3506-3513	version	abstract[221]	new[221]	_	_
18-8	3514-3517	4.0	abstract[221]	new[221]	_	_
18-9	3518-3519	,	_	_	_	_
18-10	3520-3527	whereas	_	_	_	_
18-11	3528-3531	the	event[223]	giv[223]	coref	20-3[231_223]
18-12	3532-3540	COLUMBUS	place|event[223]	giv|giv[223]	coref	22-2
18-13	3541-3546	trial	event[223]	giv[223]	_	_
18-14	3547-3551	used	_	_	_	_
18-15	3552-3559	version	abstract[224]	new[224]	_	_
18-16	3560-3564	4.03	abstract[224]	new[224]	_	_
18-17	3565-3566	.	_	_	_	_

#Text=The primary source of data on adverse drug reactions was the available U.S. prescribing information .
19-1	3567-3570	The	abstract[225]	new[225]	coref	19-11[230_225]
19-2	3571-3578	primary	abstract[225]	new[225]	_	_
19-3	3579-3585	source	abstract[225]	new[225]	_	_
19-4	3586-3588	of	abstract[225]	new[225]	_	_
19-5	3589-3593	data	abstract[225]|abstract[226]	new[225]|giv[226]	coref	20-1[232_226]
19-6	3594-3596	on	abstract[225]|abstract[226]	new[225]|giv[226]	_	_
19-7	3597-3604	adverse	abstract[225]|abstract[226]|event[228]	new[225]|giv[226]|new[228]	_	_
19-8	3605-3609	drug	abstract[225]|abstract[226]|substance|event[228]	new[225]|giv[226]|giv|new[228]	_	_
19-9	3610-3619	reactions	abstract[225]|abstract[226]|event[228]	new[225]|giv[226]|new[228]	_	_
19-10	3620-3623	was	_	_	_	_
19-11	3624-3627	the	abstract[230]	giv[230]	coref	22-10[247_230]
19-12	3628-3637	available	abstract[230]	giv[230]	_	_
19-13	3638-3642	U.S.	place|abstract[230]	giv|giv[230]	_	_
19-14	3643-3654	prescribing	abstract[230]	giv[230]	_	_
19-15	3655-3666	information	abstract[230]	giv[230]	_	_
19-16	3667-3668	.	_	_	_	_

#Text=The additional adverse event data for the dabrafenib plus trametinib combination was derived from the COMBI-d trial .
20-1	3669-3672	The	abstract[232]	giv[232]	_	_
20-2	3673-3683	additional	abstract[232]	giv[232]	_	_
20-3	3684-3691	adverse	event[231]|abstract[232]	giv[231]|giv[232]	coref	20-15[237_231]
20-4	3692-3697	event	event[231]|abstract[232]	giv[231]|giv[232]	_	_
20-5	3698-3702	data	abstract[232]	giv[232]	_	_
20-6	3703-3706	for	abstract[232]	giv[232]	_	_
20-7	3707-3710	the	abstract[232]|animal[233]|abstract[235]	giv[232]|giv[233]|giv[235]	coref	21-2[241_235]
20-8	3711-3721	dabrafenib	abstract[232]|animal[233]|abstract[235]	giv[232]|giv[233]|giv[235]	_	_
20-9	3722-3726	plus	abstract[232]|abstract[235]	giv[232]|giv[235]	_	_
20-10	3727-3737	trametinib	abstract[232]|object|abstract[235]	giv[232]|giv|giv[235]	_	_
20-11	3738-3749	combination	abstract[232]|abstract[235]	giv[232]|giv[235]	_	_
20-12	3750-3753	was	_	_	_	_
20-13	3754-3761	derived	_	_	_	_
20-14	3762-3766	from	_	_	_	_
20-15	3767-3770	the	event[237]	giv[237]	coref	21-8[243_237]
20-16	3771-3778	COMBI-d	abstract|event[237]	giv|giv[237]	_	_
20-17	3779-3784	trial	event[237]	giv[237]	_	_
20-18	3785-3786	.	_	_	_	_

#Text=For the cobimetinib plus vemurafenib combination , the coBRIM trial was utilized .
21-1	3787-3790	For	_	_	_	_
21-2	3791-3794	the	abstract[241]	giv[241]	coref	22-16[251_241]
21-3	3795-3806	cobimetinib	substance|abstract[239]|abstract[241]	giv|giv[239]|giv[241]	_	_
21-4	3807-3811	plus	abstract[239]|abstract[241]	giv[239]|giv[241]	_	_
21-5	3812-3823	vemurafenib	abstract[239]|person|abstract[241]	giv[239]|giv|giv[241]	_	_
21-6	3824-3835	combination	abstract[241]	giv[241]	_	_
21-7	3836-3837	,	_	_	_	_
21-8	3838-3841	the	event[243]	giv[243]	_	_
21-9	3842-3848	coBRIM	abstract|event[243]	giv|giv[243]	_	_
21-10	3849-3854	trial	event[243]	giv[243]	_	_
21-11	3855-3858	was	_	_	_	_
21-12	3859-3867	utilized	_	_	_	_
21-13	3868-3869	.	_	_	_	_

#Text=The COLUMBUS study was utilized as a source of additional information for adverse events for the encorafenib plus binimetinib combination .
22-1	3870-3873	The	abstract[245]	new[245]	_	_
22-2	3874-3882	COLUMBUS	place|abstract[245]	giv|new[245]	_	_
22-3	3883-3888	study	abstract[245]	new[245]	_	_
22-4	3889-3892	was	_	_	_	_
22-5	3893-3901	utilized	_	_	_	_
22-6	3902-3904	as	_	_	_	_
22-7	3905-3906	a	abstract[246]	new[246]	_	_
22-8	3907-3913	source	abstract[246]	new[246]	_	_
22-9	3914-3916	of	abstract[246]	new[246]	_	_
22-10	3917-3927	additional	abstract[246]|abstract[247]	new[246]|giv[247]	_	_
22-11	3928-3939	information	abstract[246]|abstract[247]	new[246]|giv[247]	_	_
22-12	3940-3943	for	abstract[246]|abstract[247]	new[246]|giv[247]	_	_
22-13	3944-3951	adverse	abstract[246]|abstract[247]|event[248]	new[246]|giv[247]|new[248]	_	_
22-14	3952-3958	events	abstract[246]|abstract[247]|event[248]	new[246]|giv[247]|new[248]	_	_
22-15	3959-3962	for	abstract[246]|abstract[247]|event[248]	new[246]|giv[247]|new[248]	_	_
22-16	3963-3966	the	abstract[246]|abstract[247]|event[248]|abstract[249]|abstract[251]	new[246]|giv[247]|new[248]|giv[249]|giv[251]	_	_
22-17	3967-3978	encorafenib	abstract[246]|abstract[247]|event[248]|abstract[249]|abstract[251]	new[246]|giv[247]|new[248]|giv[249]|giv[251]	_	_
22-18	3979-3983	plus	abstract[246]|abstract[247]|event[248]|abstract[251]	new[246]|giv[247]|new[248]|giv[251]	_	_
22-19	3984-3995	binimetinib	abstract[246]|abstract[247]|event[248]|abstract|abstract[251]	new[246]|giv[247]|new[248]|giv|giv[251]	_	_
22-20	3996-4007	combination	abstract[246]|abstract[247]|event[248]|abstract[251]	new[246]|giv[247]|new[248]|giv[251]	_	_
22-21	4008-4009	.	_	_	_	_
